Ontology type: schema:ScholarlyArticle Open Access: True
2012-10-19
AUTHORSM. R. McClung, A. Balske, D. E. Burgio, D. Wenderoth, R. R. Recker
ABSTRACTBone mineral density response to once weekly delayed-release formulation of risedronate, given before or following breakfast, was non-inferior to that seen with traditional immediate-release risedronate given daily before breakfast. Delayed-release risedronate is a convenient dosing regimen for oral bisphosphonate therapy that might avoid poor compliance.IntroductionThis 2-year, randomized, controlled, non-inferiority study assessed the efficacy and safety of a delayed-release (DR) 35-mg weekly oral formulation of risedronate that allows subjects to take their weekly risedronate dose before or immediately after breakfast. Results from the first year of the study were published previously (McClung et al. Osteoporos Int 23(1):267-276, 2012); we now report the final results after 2 years.MethodsWomen with postmenopausal osteoporosis were randomly assigned to receive risedronate 5 mg immediate-release (IR) daily (n = 307) at least 30 min before breakfast, or risedronate 35 mg DR weekly, either immediately following breakfast (FB, n = 307) or at least 30 min before breakfast (BB, n = 308). Bone mineral density (BMD), bone turnover markers (BTMs), fractures, adverse events, and bone histomorphometry were evaluated.ResultsA total of 248 subjects (80.8 %) in the IR daily group, 234 subjects (76.2 %) in the DR FB weekly group, and 240 subjects (77.9 %) in the DR BB weekly group completed the 2-year study. After 2 years of treatment, BMD increases at the lumbar spine and total hip with the weekly DR doses similar to or greater than that with the IR daily dose. Decreases in BTMs were similar or significantly lower in the DR groups. Bone histomorphometry results did not differ among the DR weekly and the IR daily formulations. The three regimens were similarly well tolerated.ConclusionsRisedronate 35 mg DR weekly is as effective and as well tolerated as risedronate 5 mg IR daily, and will allow subjects to take their weekly risedronate dose immediately after breakfast. More... »
PAGES301-310
http://scigraph.springernature.com/pub.10.1007/s00198-012-2175-7
DOIhttp://dx.doi.org/10.1007/s00198-012-2175-7
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1044083426
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/23079690
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Clinical Sciences",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Administration, Oral",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Bone Density",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Bone Density Conservation Agents",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Delayed-Action Preparations",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Double-Blind Method",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Drug Administration Schedule",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Etidronic Acid",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Female",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Femur",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Hip Joint",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Lumbar Vertebrae",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Middle Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Osteoporosis, Postmenopausal",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Risedronic Acid",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Treatment Outcome",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Oregon Osteoporosis Center, 5050 NE Hoyt, Suite 626, 97213, Portland, OR, USA",
"id": "http://www.grid.ac/institutes/grid.240531.1",
"name": [
"Oregon Osteoporosis Center, 5050 NE Hoyt, Suite 626, 97213, Portland, OR, USA"
],
"type": "Organization"
},
"familyName": "McClung",
"givenName": "M. R.",
"id": "sg:person.01202365465.00",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01202365465.00"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Abbott Laboratories, Abbott Park, IL, USA",
"id": "http://www.grid.ac/institutes/grid.417574.4",
"name": [
"Abbott Laboratories, Abbott Park, IL, USA"
],
"type": "Organization"
},
"familyName": "Balske",
"givenName": "A.",
"id": "sg:person.01026402633.23",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026402633.23"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "The Procter and Gamble Company, Mason, OH, USA",
"id": "http://www.grid.ac/institutes/grid.418758.7",
"name": [
"The Procter and Gamble Company, Mason, OH, USA"
],
"type": "Organization"
},
"familyName": "Burgio",
"givenName": "D. E.",
"id": "sg:person.01074516033.39",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01074516033.39"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Warner Chilcott Deutschland GmbH, Weiterstadt, Germany",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Warner Chilcott Deutschland GmbH, Weiterstadt, Germany"
],
"type": "Organization"
},
"familyName": "Wenderoth",
"givenName": "D.",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Osteoporosis Research Center, Creighton University, Omaha, NE, USA",
"id": "http://www.grid.ac/institutes/grid.254748.8",
"name": [
"Osteoporosis Research Center, Creighton University, Omaha, NE, USA"
],
"type": "Organization"
},
"familyName": "Recker",
"givenName": "R. R.",
"id": "sg:person.016325222544.69",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016325222544.69"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1007/s002230001146",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1004533024",
"https://doi.org/10.1007/s002230001146"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00198-009-0893-2",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1037232817",
"https://doi.org/10.1007/s00198-009-0893-2"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00223-002-2104-4",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1026675556",
"https://doi.org/10.1007/s00223-002-2104-4"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00223-003-0042-4",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1034121766",
"https://doi.org/10.1007/s00223-003-0042-4"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00198-012-2056-0",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1035221448",
"https://doi.org/10.1007/s00198-012-2056-0"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00223-004-0039-7",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1046491481",
"https://doi.org/10.1007/s00223-004-0039-7"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00223-004-0286-7",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1007415759",
"https://doi.org/10.1007/s00223-004-0286-7"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s001980050010",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1005303812",
"https://doi.org/10.1007/s001980050010"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00198-011-1791-y",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1040344660",
"https://doi.org/10.1007/s00198-011-1791-y"
],
"type": "CreativeWork"
}
],
"datePublished": "2012-10-19",
"datePublishedReg": "2012-10-19",
"description": "Bone mineral density response to once weekly delayed-release formulation of risedronate, given before or following breakfast, was non-inferior to that seen with traditional immediate-release risedronate given daily before breakfast. Delayed-release risedronate is a convenient dosing regimen for oral bisphosphonate therapy that might avoid poor compliance.IntroductionThis 2-year, randomized, controlled, non-inferiority study assessed the efficacy and safety of a delayed-release (DR) 35-mg weekly oral formulation of risedronate that allows subjects to take their weekly risedronate dose before or immediately after breakfast. Results from the first year of the study were published previously (McClung et al. Osteoporos Int 23(1):267-276, 2012); we now report the final results after 2\u00a0years.MethodsWomen with postmenopausal osteoporosis were randomly assigned to receive risedronate 5\u00a0mg immediate-release (IR) daily (n\u2009=\u2009307) at least 30\u00a0min before breakfast, or risedronate 35\u00a0mg DR weekly, either immediately following breakfast (FB, n\u2009=\u2009307) or at least 30\u00a0min before breakfast (BB, n\u2009=\u2009308). Bone mineral density (BMD), bone turnover markers (BTMs), fractures, adverse events, and bone histomorphometry were evaluated.ResultsA total of 248 subjects (80.8\u00a0%) in the IR daily group, 234 subjects (76.2\u00a0%) in the DR FB weekly group, and 240 subjects (77.9\u00a0%) in the DR BB weekly group completed the 2-year study. After 2\u00a0years of treatment, BMD increases at the lumbar spine and total hip with the weekly DR doses similar to or greater than that with the IR daily dose. Decreases in BTMs were similar or significantly lower in the DR groups. Bone histomorphometry results did not differ among the DR weekly and the IR daily formulations. The three regimens were similarly well tolerated.ConclusionsRisedronate 35\u00a0mg DR weekly is as effective and as well tolerated as risedronate 5\u00a0mg IR daily, and will allow subjects to take their weekly risedronate dose immediately after breakfast.",
"genre": "article",
"id": "sg:pub.10.1007/s00198-012-2175-7",
"isAccessibleForFree": true,
"isPartOf": [
{
"id": "sg:journal.1100834",
"issn": [
"0937-941X",
"1433-2965"
],
"name": "Osteoporosis International",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "1",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "24"
}
],
"keywords": [
"bone turnover markers",
"bone mineral density",
"risedronate 5",
"postmenopausal osteoporosis",
"weekly group",
"bone mineral density response",
"oral bisphosphonate therapy",
"non-inferiority study",
"years of treatment",
"delayed-release formulation",
"bisphosphonate therapy",
"risedronate 35",
"turnover markers",
"adverse events",
"daily group",
"daily dose",
"total hip",
"DR group",
"daily formulation",
"poor compliance",
"ResultsA total",
"mineral density",
"bone histomorphometry",
"lumbar spine",
"oral formulation",
"risedronate",
"breakfast",
"weekly",
"dose",
"osteoporosis",
"histomorphometry results",
"first year",
"subjects",
"treatment",
"group",
"years",
"regimen",
"MethodsWomen",
"regimens",
"therapy",
"min",
"hip",
"histomorphometry",
"doses",
"daily",
"spine",
"study",
"IntroductionThis",
"efficacy",
"total",
"markers",
"safety",
"fractures",
"compliance",
"response",
"decrease",
"results",
"events",
"final results",
"formulation",
"density response",
"density",
"IR"
],
"name": "Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years",
"pagination": "301-310",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1044083426"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1007/s00198-012-2175-7"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"23079690"
]
}
],
"sameAs": [
"https://doi.org/10.1007/s00198-012-2175-7",
"https://app.dimensions.ai/details/publication/pub.1044083426"
],
"sdDataset": "articles",
"sdDatePublished": "2022-08-04T16:59",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_560.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1007/s00198-012-2175-7"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00198-012-2175-7'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00198-012-2175-7'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00198-012-2175-7'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00198-012-2175-7'
This table displays all metadata directly associated to this object as RDF triples.
267 TRIPLES
21 PREDICATES
114 URIs
97 LITERALS
24 BLANK NODES